Related Experiment Video

Updated: May 7, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

How Should We Treat Depression in Patients with Cardiovascular Disease?

Ian M Kronish1, David J Krupka, Karina W Davidson

  • 1Department of Medicine, Columbia University Medical Center, New York, New York.

Dialogues in Cardiovascular Medicine : DCM
|September 17, 2013
PubMed

Insights

Depression is common in cardiovascular disease (CVD) patients, impacting prognosis. Effective treatments exist, but routine screening for all CVD patients requires further risk-benefit analysis.

Area of Science:

  • Cardiology
  • Psychiatry
  • Clinical Medicine

Background:

  • Depression is highly prevalent in patients with cardiovascular disease (CVD).
  • Depression is linked to poorer cardiovascular outcomes and reduced quality of life.
  • Existing depression treatments offer modest but significant benefits for CVD patients.

Purpose of the Study:

  • To review the safety and efficacy of depression treatments in cardiovascular disease patients.
  • To evaluate treatment strategies for depression in the context of cardiovascular health.
  • To inform recommendations regarding depression screening and management in CVD populations.

Main Methods:

  • Systematic review of existing literature on depression treatment in CVD.
  • Analysis of antidepressant safety profiles in cardiac patients.
  • Evaluation of combination therapy versus monotherapy for depression in CVD.

Main Results:

  • Certain antidepressant classes are safe for cardiac patients; tricyclics should be avoided.
  • Combined medication and psychotherapy, with treatment intensification, is more effective than single interventions.
  • Modest but clinically significant reductions in depressive symptoms are achievable.

Conclusions:

  • Depression treatment in CVD patients shows promise for improving cardiovascular prognosis.
  • Patient-centered approaches involving shared decision-making and treatment intensification are recommended.
  • Routine screening for all CVD patients may be premature due to cost and knowledge gaps regarding mild/moderate depression.

More Related Videos

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...